TheraCryf PLC
8EV
Company Profile
Business description
TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships for its programs with mid-sized and large pharmaceutical companies. The company's pipeline includes Ox-1 - Substance Use Disorders (SUDs) / Anxiety, DAT - Fatigue and Narcolepsy, SFX-01, and SFX-01- Neurodevelopmental Disorders.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
9
Stocks News & Analysis
stocks
ASX listed bank overvalued despite strong earnings
Profit beats drive shares higher for Australia’s largest asset manager.
stocks
After earnings, is Amazon a buy, a sell, or fairly valued?
After the launch of Amazon Supply Chain Services, here’s what we think of the stock.
stocks
ASX retail share expected to recover despite choppy conditions
Weakening consumer demand a temporary headwind for ASX retailer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,942.40 | 14.50 | 0.16% |
| CAC 40 | 8,056.38 | 56.19 | -0.69% |
| DAX 40 | 24,350.28 | 11.65 | 0.05% |
| Dow JONES (US) | 49,611.06 | 1.90 | 0.00% |
| FTSE 100 | 10,269.43 | 36.36 | 0.36% |
| HKSE | 26,406.84 | 13.13 | 0.05% |
| NASDAQ | 26,297.21 | 50.13 | 0.19% |
| Nikkei 225 | 62,417.88 | 295.77 | -0.47% |
| NZX 50 Index | 13,210.48 | 35.35 | 0.27% |
| S&P 500 | 7,417.52 | 18.59 | 0.25% |
| S&P/ASX 200 | 8,701.80 | 11.50 | 0.13% |
| SSE Composite Index | 4,225.02 | 45.07 | 1.08% |